Failed trial nixes another FDA approval, this time for BMS’ Istodax
pharmaphorum
AUGUST 4, 2021
The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).
Let's personalize your content